by Lauren Taylor from In The Cloud Copy A variance in the amount or makeup of the bacteria in a person’s gut, called dysbiosis, could have strong implications for the…
In a recent press release, biopharmaceutical company Acceleron Pharma, Inc. ("Acceleron") announced that its investigational drug candidate sotatercept received Orphan designation from the European Commission (EC) for the treatment of…
According to Biospace, Acceleron Pharma has presented preliminary data from their ongoing Phase 2 trial of sotatercept, a treatment for pulmonary arterial hypertension (PAH). The study, titled SPECTRA, is designed…
The PAH Today National Broadcast "Moving Forward" Saturday, November 14th, 2020 This online webinar event will be a critical chance for pulmonary arterial hypertension (PAH) caregivers and patients from around…
The PAH Today National Broadcast "The Pathways to Treatment" Saturday, November 7th, 2020 This online webinar event will be a critical chance for pulmonary arterial hypertension (PAH) caregivers and patients…
New Trial A Phase 1A trial for GMA301 was completed this year in Australia for pulmonary arterial hypertension (PAH). This trial demonstrated a positive safety profile for a range of…
The PAH Today National Broadcast "How Decisions Today Can Shape The Future" Saturday, October 24th, 2020 This online webinar event will be a critical chance for pulmonary arterial hypertension (PAH)…
According to a story from GlobeNewswire, the medical device company SoniVie announced recently that the US Food and Drug Administration (FDA) has granted approval for its Investigational Device Exemption (IDE).…
The PAH Today National Broadcast Saturday, October 17th, 2020 This online webinar event will be a critical chance for pulmonary arterial hypertension (PAH) caregivers and patients from around the country…
Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson reported that they submitted a New Drug Application (NDA) for intravenously administered UPTRAVI (selexipag). The therapy is designed to treat…
Medical professionals have already discovered a number of genes that play a role in pulmonary arterial hypertension (PAH), but according to LabRoots, they have found a new one. The ABCC8…
According to a story from Pharmaceutical Business Review, the pharmaceutical company Bayer has recently announced encouraging findings from its phase 4 clinical study. This trial was testing the drug riociguat…
by Lauren Taylor from In The Cloud Copy Pediatric pulmonary arterial hypertension is a disease in which the blood flow leaving the right side of the heart faces increased resistance…
Acceleron Pharma has released the results from Phase 2 of their PULSAR trial, which studied sotatercept as a treatment for pulmonary arterial hypertension. Researchers are very excited by the positive…
Pulmonary hypertension can be caused by a variety of other conditions, often making it difficult to distinguish. A problem that medical professionals often encounter is differentiating pulmonary arterial hypertension (PAH)…
For most drug therapies, researchers test on animal models of a disease before testing on humans. Recently, using microRNA-483, a small RNA molecule, on rat models of PAH reduced…
According to Healio, US veterans affected by pulmonary arterial hypertension are typically not treated with exercise rehabilitation, despite the fact that many medical professionals believe that utilizing exercise rehabilitation in…
Recently, researchers from European Molecular Biology Laboratory (EMBL) looked to understand the cause of pulmonary arterial hypertension (PAH). They collaborated with Stanford University through the Life Sciences Alliance. Because…
A recent Phase 4 study has shown that Opsumit can improve function of the right heart ventricle for patients with pulmonary arterial hypertension (PAH). The right ventricle pumps blood to…
The FDA recently granted Orphan Drug status to CS1, a drug therapy from Cereno Scientific, according to Pulmonary Hypertension News. CS1 is designed to provide safe and effective treatment for…
According to a story from globenewswire.com, the biopharmaceutical company Liquidia Technologies, Inc. just announced that the company's New Drug Application (NDA) has been officially accepted by the US Food and…
According to a story from Pulmonary Hypertension News, the results of a recent phase 3 clinical trial have determined that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) stand…
According to a story from Pulmonary Advisor, the results of a recent analysis led researchers to conclude that systemic anticoagulation therapy can be beneficial for patients with idiopathic pulmonary arterial…
As originally reported in Global Data, the FDA has just given the final approval for a treatment options for pulmonary arterial hypertension (PAH) called 'Bosentan.' Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension…
According to a story from consultant360.com, a recent study was conducted in order to determine if racial ancestry had any impacts on outcomes in the rare disease pulmonary arterial hypertension…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
